AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Cancer or benign tumor

cervical carcinoma

A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma.

🔔 Follow weekly
🧬8566genes / proteins with evidence
💊69drugs and clinical candidates
🧪12+recruiting trials worldwide
✅15phase 3
📈35phase 2
🧬

Understand cervical carcinoma

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Cervical cancer is cancer that starts in the cells of the cervix. The cervix is part of the female reproductive system. It is the lower, narrow end of the uterus (womb), which opens into the vagina (birth canal).

Cervical cancer usually develops slowly. Before cervical cells become cancer, they start to look abnormal. These cells are called "precancers." If they aren't destroyed or removed, they may become cancer cells that grow out of control and spread to other parts of your body.

Screening tests for cervical cancer can help find abnormal cells so you can get treatment to prevent cervical cancer. These tests can also find cervical cancer early when it's usually easier to treat.

From MedlinePlus: Cervical Cancer (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for cervical carcinoma itself.

🤖

AI briefing

Where the science on cervical carcinoma stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens cervical carcinoma.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.65
FBXW7 F-box and WD repeat domain containing 7PROTACsmall molecule🧊 AlphaFold structure ↗ 0.62
STK11 serine/threonine kinase 11PROTACsmall molecule🧊 AlphaFold structure ↗ 0.61
EP300 EP300 lysine acetyltransferasePROTACsmall molecule🧊 AlphaFold structure ↗ 0.60
KMT2D lysine methyltransferase 2DPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.60
KMT2C lysine methyltransferase 2CPROTACsmall molecule🧊 AlphaFold structure ↗ 0.59
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.54
KRAS KRas proto-oncogene, GTPasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.54
PTEN phosphatase and tensin homologPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.53
NOTCH1 notch receptor 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.53
FAT1 FAT atypical cadherin 1PROTACantibody🧊 AlphaFold structure ↗ 0.53
FGFR2 fibroblast growth factor receptor 2PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.53
ERBB2 erb-b2 receptor tyrosine kinase 2PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.52
MAPK1 mitogen-activated protein kinase 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.52
RB1 RB transcriptional corepressor 1PROTACsmall molecule🧊 AlphaFold structure ↗ 0.48

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to cervical carcinoma, by how far it has got
In phase 2 / 3 · 20
AtezolizumabProgrammed cell death 1 ligand 1 inhibitorPhase 3
BevacizumabVascular endothelial growth factor A inhibitorPhase 3
CarboplatinPhase 3
CatequentinibVascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth fact…Phase 3
CisplatinPhase 3
Epoetin BetaErythropoietin receptor agonistPhase 3
Show all 20
FluorouracilThymidylate synthase inhibitorPhase 3
GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Phase 3
NelfinavirHuman immunodeficiency virus type 1 protease inhibitorPhase 3
PaclitaxelTubulin inhibitorPhase 3
S1?Phase 3
TirapazaminePhase 3
TopotecanDNA topoisomerase I inhibitorPhase 3
Topotecan HydrochlorideDNA topoisomerase I inhibitorPhase 3
VinorelbineTubulin inhibitorPhase 3
AldesleukinInterleukin-2 receptor agonistPhase 2
Antineoplaston A10Phase 2
Arsenic TrioxideThioredoxin reductase 1 inhibitorPhase 2
BelotecanDNA topoisomerase I inhibitorPhase 2
Bryostatin 1Phase 2
Early trials · 17
AmifostinePhase 1/2
BemarituzumabFibroblast growth factor receptor 2 inhibitor; Low affinity immunoglobulin gamma Fc regio…Phase 1/2
Bizalimogene RalaplasmidPhase 1/2
CelecoxibCyclooxygenase-2 inhibitorPhase 1/2
EtigilimabT-cell immunoreceptor with Ig and ITIM domains inhibitorPhase 1/2
NivolumabProgrammed cell death protein 1 inhibitorPhase 1/2
Show all 17
Rocakinogene SifuplasmidPhase 1/2
EverolimusFK506-binding protein 1A inhibitorPhase 1
FenofibratePeroxisome proliferator-activated receptor alpha agonistPhase 1
InfigratinibFibroblast growth factor receptor inhibitorPhase 1
IrinotecanDNA topoisomerase I inhibitorPhase 1
MulnitorsenPhase 1
MurlentamabPhase 1
TalazoparibPoly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitorPhase 1
TislelizumabProgrammed cell death protein 1 inhibitorPhase 1
TivantinibHepatocyte growth factor receptor inhibitorPhase 1
VeliparibPARP 1, 2 and 3 inhibitorPhase 1
🧪

Recruiting trials

Worldwide, open to new patients now
The Ohio State University (OSU) SCREEN Community ProgramNCT06666192 · NA · 📍 ColumbusTirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCCNCT05941338 · Phase 2 · 📍 GuangzhouVMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or…NCT03556228 · Phase 1, Phase 2 · 📍 Santa RosaSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)NCT06780111 · Phase 1, Phase 2 · 📍 PittsburghA Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastr…NCT07692204 · Phase 2 · 📍 ShanghaiTumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell CarcinomaNCT06606028 · n/a · 📍 San FranciscoPostoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal CarcinomaNCT05937438 · Phase 1, Phase 2 · 📍 HefeiNanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid CarcinomaNCT07218315 · NA · 📍 SarasotaNeoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC …NCT04807140 · Phase 2 · 📍 GuangzhouA Study of MT-4561 in Patients With Various Advanced Solid TumorsNCT06943521 · Phase 1, Phase 2 · 📍 Los AngelesA Clinical Study of LM103 Injection in the Treatment of Advanced Solid TumorsNCT05366478 · Phase 1 · 📍 TianjinIntra-lesional Tumor Boost for Bulky Cervical CancerNCT07435376 · Phase 2 · 📍 Seongnam-si Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy